Future Fertility is a tech startup that leverages artificial intelligence (AI) to help users improve their chances of getting pregnant. The company recently announced the close of its Series A funding round to expand its business to new clinics around the world.
How Future Fertility Works and Early Signs of Business Growth
Healthtech startup Future Fertility focuses its AI on generating higher success rates for in vitro fertilization (IVF). IVF success rates currently range anywhere between 10% and over 50% depending on a number of factors including age, health, prior pregnancies, and more. Additionally, IVF prices are also high with just one cycle costing between $6,000 and $15,000. With a low success rate that oftentimes requires multiple cycles, the cost for IVF can rise significantly.
Future Fertility uses AI visualization to detect specific features on a woman’s egg that can provide insight into the likelihood of a successful pregnancy. By doing so, the company can more accurately predict how many egg cycles and IVF treatments it will take to conceive. Additionally, the data can provide more upfront information for prospective IVF patients.
For fertility clinics, using the AI software developed by the startup company can reportedly increase the number of IVF cycle patients by providing them with more information and more accurate results. Future Fertility has already begun developing business partnerships with several clinics around the world.
The startup company is entering into the rapidly growing fertility market estimated to be worth over $29 billion in 2021. The market is projected to reach a value of over $45 billion by 2027 at a compound annual growth rate (CAGR) of 4.7%. Major players in the fertility market are Boston IVF Fertility Clinic, INVO Bioscience, Cook Medical, Celmatix, and Fujifilm Irvine Scientific. Future Fertility’s AI software is a supportive technology, meaning that it could be used by major industry players without the need to fight for market share.
Future Fertility Funding Round and Plans for Business Growth
The startup company recently announced that it raised an undisclosed amount from its Series A funding round. The funding round was led by M Ventures with participation from Whitecap Venture Partners.
The startup company plans to use the new funding to develop new business partnerships with clinics in the United States (US). Additionally, Future Fertility plans to add oocyte scoring to its current offerings. Oocyte scoring is a non-invasive way to assess the quality of an egg for patients already going through the IVF cycle. Other plans include investing in research and development for future AI-powered solutions for the IVF cycle.
When commenting on the latest funding round and the AI software, co-founder and Chief Medical Officer of Future Fertility Dr. Dan Nayot said, “Our technology has been proven to outperform embryologists in predicting the reproductive potential of an egg and can support decision-making in the IVF and egg freezing journeys. Our solutions finally add a significant missing diagnostic parameter to the IVF process, adding transparency to routine sperm and embryo assessment by uniquely addressing egg viability. Creating a validated egg scoring system has been a major challenge in the field and has now been made possible by AI. I am passionate about patient centricity and immensely proud that Future Fertility can address this gap and enable physicians like myself to better treat our patients.”
Tom Price is a writer focusing on entertainment and sports features. He has a degree from NYU in English with a minor in Creative Writing. He has been previously published for Washington Square News, Dignitas, CBR, and Numbers on the Boards.